Home    Back

Mavorixafor    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency11

65. Primary immunodeficiency    [ 413 clinical trials,   581 drugs,   (DrugBank: 97 drugs),   68 drug target genes,   202 drug target pathways]
Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "Telangiectasia ataxia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "IMyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "CC1r deficiency", "CC1s deficiency", "CC2 deficiency", "CC3 deficiency", "CC4 deficiency", "CC5 deficiency", "CC6 deficiency", "CC7 deficiency", "CC8 deficiency", "CC9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
11 / 413 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-001153-10-GB
(EUCTR)		21/12/202029/06/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
2EUCTR2019-001153-10-DE
(EUCTR)		20/10/202026/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
3EUCTR2019-001153-10-AT
(EUCTR)		16/10/202024/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
4EUCTR2019-001153-10-NL
(EUCTR)		09/09/202006/04/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;Canada;Belgium;Poland;Romania;Australia;Denmark;Netherlands;Germany;Korea, Republic of
5NCT04154488
(ClinicalTrials.gov)		August 15, 20204/11/2019A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia DisordersA Phase 1B, Open-Label, Multicenter Study of Mavorixafor in Patients With Severe Congenital Neutropenia and Chronic Neutropenia DisordersNeutropeniaDrug: MavorixaforX4 PharmaceuticalsNULLNot yet recruiting12 YearsN/AAll45Phase 1United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2019-001153-10-PL
(EUCTR)		27/04/202009/03/2020A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of
7EUCTR2019-001153-10-ES
(EUCTR)		02/03/202002/12/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		28Phase 3Portugal;United States;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Netherlands;Germany;Korea, Republic of
8EUCTR2019-001153-10-HU
(EUCTR)		08/01/202008/11/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		28Phase 3Portugal;United States;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Netherlands;Germany;Korea, Republic of
9EUCTR2019-001153-10-DK
(EUCTR)		16/12/201921/10/2019A treatment study in patients with WHIM Syndrome.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12]Product Name: Mavorixafor
Product Code: X4P-001
INN or Proposed INN: Mavorixafor		X4 Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		28Phase 3United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Denmark;Australia;Germany;Netherlands;Korea, Republic of
10NCT03995108
(ClinicalTrials.gov)		October 17, 201919/6/2019Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label ExtensionWHIM SyndromeDrug: Mavorixafor;Drug: PlaceboX4 PharmaceuticalsNULLRecruiting12 YearsN/AAll28Phase 3United States;Australia;Austria;Denmark;France;Hungary;Italy;Korea, Republic of;Spain
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11NCT03005327
(ClinicalTrials.gov)		December 201620/12/2016A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeA Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM SyndromeWHIM SyndromeDrug: X4P-001X4 PharmaceuticalsNULLActive, not recruiting18 YearsN/AAll15Phase 2United States;Australia

Back to top